NRx: Higher Likelihood of Surviving, Recovering from Critical COVID-19 with ZYESAMI

 

• Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population
  

• Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir

• NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests

• US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients

https://finance.yahoo.com/news/nrx-pharmaceuticals-identifies-significantly-higher-113100540.html